Starting Dose of Olanzapine for Adults
The recommended starting dose of oral olanzapine for adults is 5-10 mg once daily, with most patients beginning at 5 mg and titrating to a target dose of 10 mg/day within several days. 1
Standard Oral Dosing
- Begin with 5-10 mg orally once daily without regard to meals, with a target dose of 10 mg/day reached within several days for schizophrenia 1
- The FDA-approved dosing demonstrates efficacy in the 10-15 mg/day range, though doses above 10 mg/day were not more efficacious than 10 mg/day in clinical trials 1
- Maximum recommended dose is 20 mg/day; olanzapine is not indicated for doses above this threshold 1
- Dose adjustments should occur at intervals of at least 1 week, as steady-state concentrations require approximately one week to achieve 1
Lower Starting Doses for Specific Populations
Start at 2.5-5 mg in patients with risk factors for slower metabolism or increased sensitivity: 2, 1
- Geriatric patients (≥65 years) 1
- Debilitated patients 1
- Patients predisposed to hypotensive reactions 1
- Nonsmoking female patients ≥65 years (combination of factors resulting in slower metabolism) 1
- Hepatic impairment - reduced starting dose of 2.5 mg is recommended 2
- Alzheimer's disease patients - 2.5 mg starting dose 2
Intramuscular Dosing for Acute Agitation
- Standard IM dose: 10 mg for acute agitation associated with schizophrenia or bipolar mania 1
- Alternative doses of 2.5 mg, 5 mg, or 7.5 mg IM can be used based on clinical factors 3
- Geriatric patients: 5 mg IM should be considered 1
- Debilitated or sensitive patients: 2.5 mg IM 1
- Clinical trials demonstrated efficacy with IM doses ranging from 2.5-10 mg 3
Important Clinical Considerations
- Monitor for orthostatic hypotension, particularly with IM administration - assess patients before subsequent doses 2, 1
- Avoid combining with benzodiazepines when possible due to risk of oversedation, respiratory depression, and reported fatalities with high-dose olanzapine 2
- Common side effects include drowsiness, sedation, weight gain (approximately 40% of patients), dry mouth, and dizziness 2, 4
- Weight gain is more likely with higher starting doses and in underweight patients at baseline 4